Results 121 to 130 of about 423,412 (333)
A biophysical network model reveals the link between deficient inhibitory cognitive control and major neurotransmitter and neural connectivity hypotheses in schizophrenia [PDF]
arXiv, 2021 We address a biophysical network dynamical model to study how the modulation of dopamine (DA) activity and related N-methyl-d-aspartate (NMDA) glutamate receptor activity as well as the emerging Pre-Frontal Cortex (PFC) functional connectivity network (FCN) affect inhibitory cognitive function in schizophrenia in an antisaccade task.
arxiv
Polar Chemoreceptor Clustering by Coupled Trimers of Dimers [PDF]
Biophys J 96(2): 453-463 (2009), 2009 Receptors of bacterial chemotaxis form clusters at the cell poles, where clusters act as "antennas" to amplify small changes in ligand concentration. Interestingly, chemoreceptors cluster at multiple length scales. At the smallest scale, receptors form dimers, which assemble into stable timers of dimers.
arxiv +1 more source
Blunted Cystine–Glutamate Antiporter Function in the Nucleus Accumbens Promotes Cocaine-induced Drug Seeking [PDF]
, 2008 Repeated cocaine alters glutamate neurotransmission, in part, by reducing cystine–glutamate exchange via system xc−, which maintains glutamate levels and receptor stimulation in the extrasynaptic compartment.
Abdulhameed, Omer +5 more
core +1 more source
Antiparkinsonian Effects of a Metabotropic Glutamate Receptor 4 Agonist in MPTP-Treated Marmosets.
Journal of Parkinson's Disease, 2020 BACKGROUND Increased firing across glutamatergic synapses may contribute to both the motor dysfunction and L-DOPA-induced dyskinesia seen in Parkinson's disease.
Elizabeth Mann +5 more
semanticscholar +1 more source
Navigating the treatment landscape of Alzheimer's disease: Current strategies and future directions
Ibrain, EarlyView.Alzheimer's disease treatment is evolving rapidly, with emerging strategies targeting multiple disease pathways. This graphical abstract highlights the shift from traditional therapies to innovative approaches that hold promise for improving outcomes.
Tapas Kumar Mohapatra +4 more
wiley +1 more source
ASN Neuro, 2018 Levodopa (L-DOPA) is still the most effective drug for the treatment of Parkinson’s disease (PD). However, the long-term therapy often triggers L-DOPA-induced dyskinesia (LID).
Yixian Huang +6 more
doaj +1 more source
Frontiers in Pharmacology, 2017 Metabotropic glutamate (mGlu) receptor 5 is involved in neuroinflammation and has been shown to mediate reduced inflammation and neurotoxicity and to modify microglia polarization.
Martina Beneventano +9 more
doaj +1 more source
The activation of group II metabotropic glutamate receptors protects neonatal rat brains from oxidative stress injury after hypoxia-ischemia. [PDF]
PLoS ONE, 2018 Birth asphyxia resulting in brain hypoxia-ischemia (H-I) can cause neonatal death or lead to persistent brain damage. Recent investigations have shown that group II metabotropic glutamate receptor (mGluR2/3) activation can provide neuroprotection against
Ewelina Bratek +3 more
doaj +1 more source
Targeting glutamate metabolism in melanoma [PDF]
arXiv, 2019 The glutamate metabotropic receptor 1 (GRM1) drives oncogenesis when aberrantly activated in melanoma and several other cancers. Metabolomics reveals that patient-derived xenografts with GRM1-positive melanoma tumors exhibit elevated plasma glutamate levels associated with metastatic melanoma in vivo. Stable isotope tracing and GCMS analysis determined
arxiv
Movement Disorders, EarlyView.Abstract Background Fatigue in Parkinson's disease (PD) is a prevalent and debilitating non‐motor symptom. Despite its significant impact on quality of life, the underlying neurochemical and network‐based mechanisms remain poorly understood. Objectives This observational study applied a multimodal imaging approach to explore potential links between the
Ilaria Antonella Di Vico +14 more
wiley +1 more source